Mounjaro shots: the facts behind the once-weekly injection

The misconception that Mounjaro shots simply suppress appetite

People often describe tirzepatide as an "appetite jab", as if the pen just tells your brain to want less food. That framing is understandable (reduced appetite is one of the things patients notice first) but it sells the mechanism short. Mounjaro activates two distinct gut-hormone receptors, GIP and GLP-1, each of which plays a separate role in how your body regulates blood sugar, fat storage and feelings of fullness. Activating both at once slows how quickly food moves through your stomach, increases the hormonal signals that tell the brain the meal is done, and influences the way the body handles energy from fat. The result is a sustained reduction in how much you want to eat, combined with changes in how efficiently calories are stored. It is quite different from older medicines that simply blunted hunger through central nervous system stimulation. If you want to go deeper on the biology, our page on tirzepatide and how it works covers the receptor science in more detail.

The distinction matters practically: because the effect works through hormone pathways rather than willpower, side effects are largely gastrointestinal rather than stimulant-related. Nausea, loose stools, constipation and indigestion are the most common complaints, especially in the weeks after a dose increase. For most people they ease with time. That is not a guarantee, your prescriber is the right person to talk to if they persist.

What the clinical trial data says, and how to read it honestly

SURMOUNT-1, the pivotal phase-3 trial for tirzepatide in weight management, randomised 2,539 adults with obesity and ran for 72 weeks. At the 15 mg dose, participants lost an average of around 20–21% of their body weight. The full trial results, published in the New England Journal of Medicine, show a range of outcomes rather than a single figure, some people lost considerably more, some less. Averages in clinical trials reflect a controlled environment with structured dietary support, so treating a single percentage as a personal prediction would be misleading. What the data does confirm is the scale of the effect: NICE reviewed this evidence directly and recommended tirzepatide for NHS use in eligible adults in December 2024. You can read NICE's full appraisal of tirzepatide (TA1026) on the NICE website.

A useful cross-reference: the comparison of Mounjaro with other weight-loss medicines sets these trial figures alongside the semaglutide data from STEP 1 and the SURMOUNT-5 head-to-head, so the numbers sit in context rather than in isolation. Weight loss from Mounjaro shots is real, meaningful and evidence-backed, it is not inevitable, uniform or free of side effects, and any site that implies otherwise is not being straight with you.

Who can receive a Mounjaro shot prescription in the UK

The licensed eligibility criteria for Mounjaro in the UK are an adult with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, raised cholesterol, type 2 diabetes, obstructive sleep apnoea or prediabetes. Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance. A BMI figure alone does not determine approval, a prescriber assesses your full medical history, current medicines and any contraindications before issuing a prescription. Mounjaro shots are not licensed for anyone under 18, and they are not recommended during pregnancy, while breastfeeding or if you are actively trying to conceive.

Women taking oral contraceptives should add a non-oral method of contraception for the first four weeks of Mounjaro treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying can reduce pill absorption. NHS England's guidance on weight-management injections covers this, along with advice on HRT and what to tell an anaesthetist if you are having surgery. It is worth reading before you start.

If you are curious about how timing, frequency and missed doses are handled in practice, our guide to the gap between Mounjaro shots and the page on when to take your shot each week answer the questions prescribers field most often. For a fuller picture of the treatment overall, the Mounjaro treatment overview is the place to start.

Accessing Mounjaro shots: NHS, private and what to check about any provider

Mounjaro shots are available on the NHS in England for adults who meet NICE's eligibility criteria (TA1026), though access is being phased in gradually and waiting times vary. Many people explore private prescribing through a registered online pharmacy instead, either because they do not yet meet the NHS thresholds or because they do not want to wait. That is a reasonable choice, provided the pharmacy is legitimate. These are prescription-only medicines; any seller offering them without a clinical assessment first is operating illegally, and the MHRA has seized large quantities of fake weight-loss pens sold this way. Before placing an order anywhere, check that the pharmacy appears on the GPhC register of registered pharmacies.

On cost, the private market for Mounjaro has changed considerably since Eli Lilly revised UK list prices in September 2025. A rough sense of what to budget is useful, our Mounjaro price guide sets out the market context honestly, including what a legitimate private price should include beyond the pen itself. At nume, consultations are free and every prescription is reviewed by a GPhC-registered independent prescriber, not automated software, before anything is dispensed. If you would like to find out whether Mounjaro shots are clinically suitable for you, checking your eligibility through a free consultation is the first step.